Page results
-
This page provides information about the Modified Exercise Test.
-
This information is for patients who are about to start a course of radiotherapy to the prostate/prostate bed.
-
This page is about histiocytic disorders treated at the UCLH haematology department.
-
Once you have completed treatment for cancer at UCLH you will enter a period of follow-up care. Follow-up is an important way of monitoring your health.
-
Specialist and interventional cardiology outpatient services are provided by the Barts Heart Centre. General cardiology outpatients for local patients will continue to be provided by University College Hospital.
-
The oral and maxillofacial surgery department focuses on the delivery of care to patients with dento-alveolar needs.
-
The rhinology unit covers all aspects of nose and sinus disease including allergy, infection, inflammatory/mucosal conditions, breathing disorders and tumours.
-
This page aims to provide information about the syndrome haemophagocytic lymphohistiocytosis (HLH).
-
Our colorectal service fast-tracks investigations for the management of all suspected colorectal cancer. It also provides specialist surgical treatment for some patients within the North Central London sector who are diagnosed with bowel cancer under the NHS bowel cancer screening programme based at UCLH.
-
The FES service is for people who have an upper motor neuron neurological disorder, difficulty walking due to dropped foot and are 16 or over
File results
-
FOI/2022/0499 - Framework/ tender for services used to collect offensive and clinical waste
-
FOI/2022/0505 - Type of needles used for insulin administration to patients
-
FOI/2022/0515 - Senior staff contact details
-
FOI/2022/0536 - Head of Procurement contact details
-
FOI/2022/0551 - Procurement contact details
-
FOI/2022/0555 - Senior staff contact details
-
FOI/2022/0563 - Ambulatory cardiac monitoring
-
FOI/2022/0542 - Infection control audits from September 2020 to April 2021
-
FOI/2022/0544 - Wards/ departments that provide services to 0-17 year-olds
-
FOI/2022/0548 - Biologic and biosimilar products within Rheumatology